Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B cell lymphoma and leukemia.

Buatois V, Johnson Z, Salgado-Pires S, Papaïoannou A, Hatterer E, Chauchet X, Richard F, Barba L, Daubeuf B, Cons L, Broyer L, D'Asaro M, Matthes T, LeGallou S, Fest T, Tarte K, Clarke Hinojosa RK, Genescà Ferrer E, Ribera JM, Dey A, Bailey K, Fielding AK, Eissenberg L, Ritchey J, Rettig M, DiPersio JF, Kosco-Vilbois MH, Masternak K, Fischer N, Shang L, Ferlin WG.

Mol Cancer Ther. 2018 May 9. pii: molcanther.1095.2017. doi: 10.1158/1535-7163.MCT-17-1095. [Epub ahead of print]

PMID:
29743205
2.

Toll-Like Receptor 4 on both Myeloid Cells and Dendritic Cells Is Required for Systemic Inflammation and Organ Damage after Hemorrhagic Shock with Tissue Trauma in Mice.

Zettel K, Korff S, Zamora R, Morelli AE, Darwiche S, Loughran PA, Elson G, Shang L, Salgado-Pires S, Scott MJ, Vodovotz Y, Billiar TR.

Front Immunol. 2017 Nov 28;8:1672. doi: 10.3389/fimmu.2017.01672. eCollection 2017.

3.

Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies.

Dheilly E, Moine V, Broyer L, Salgado-Pires S, Johnson Z, Papaioannou A, Cons L, Calloud S, Majocchi S, Nelson R, Rousseau F, Ferlin W, Kosco-Vilbois M, Fischer N, Masternak K.

Mol Ther. 2017 Feb 1;25(2):523-533. doi: 10.1016/j.ymthe.2016.11.006.

4.

Selective antibody intervention of Toll-like receptor 4 activation through Fc γ receptor tethering.

Shang L, Daubeuf B, Triantafilou M, Olden R, Dépis F, Raby AC, Herren S, Dos Santos A, Malinge P, Dunn-Siegrist I, Benmkaddem S, Geinoz A, Magistrelli G, Rousseau F, Buatois V, Salgado-Pires S, Reith W, Monteiro R, Pugin J, Leger O, Ferlin W, Kosco-Vilbois M, Triantafilou K, Elson G.

J Biol Chem. 2014 May 30;289(22):15309-18. doi: 10.1074/jbc.M113.537936. Epub 2014 Apr 15.

Supplemental Content

Loading ...
Support Center